Nicox extends its financing horizon beyond Q1 2028, cash position at €8.4 million
The ophthalmology laboratory based in Biot provided an update on its financial situation as of August 31, 2026, with a cash position of €8.4 million.
The company now links its financial visibility to regulatory milestones expected for its NCX 470 eye drop in the United States.
Cash position of €8.4 million as of August 31, 2026
Nicox announced on September 2, 2026 an extension of its financing horizon, accompanied by a general status update.
As of August 31, 2026, cash and cash equivalents stood, according to an unaudited management estimate, at €8.4 million, compared to €4.1 million as of December 31, 2025.
The company states that it has significantly reduced its fixed costs. On the basis of its current structure and operations, it estimates that its cash position is sufficient to finance existing operations beyond the first quarter of 2028.
Nicox specifies that additional financing options remain available under the shareholder loan granted by Vester Finance, announced in June 2026.
The company adds that any changes in assumptions relating to estimated revenues, debt or costs could modify the estimated cash horizon.
NCX 470 milestones condition visibility beyond 2028
The financing horizon depends on regulatory milestones expected for NCX 470 in the United States.
The PDUFA date for this eye drop was announced on August 27 and set for April 30, 2027. According to Nicox, the payment of the milestone fee due upon approval of NCX 470 in the United States would finance existing operations until 2029.
Royalties expected following a commercial launch in the United States, planned by exclusive partner Kowa in the second half of 2027 subject to approval, could substantially extend the cash horizon.
NCX 470 (bimatoprost grenod) is an eye drop intended to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets, and to Kowa for the rest of the world.
Changes in development leadership
Nicox presented several developments within its management team.
Doug Hubatsch, formerly executive vice president, responsible for research and development and scientific director since December 2021, takes on the new position of chief scientific advisor and is stepping back from operational management. He will continue to support NCX 470 during the NDA review period.
Siobhan Garbutt, vice president and head of clinical development, is taking over the leadership of the development team. Present at Nicox since July 2022, she has led NCX 470 clinical activities and participated in NDA drafting.
The company also indicates that it is continuing development discussions and evaluating several strategic growth opportunities, including potential collaborations or business combinations.
